Companies › PDC*line Pharma SAS
1 active drug program in 1 registered trial: 1 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PDC*lung01 Dendritic cell vaccine loaded with synthetic peptides from lung tumor antigens (NY-ESO-1, | PRAME, MAGEA3, MAGEA4 | Phase 1 | Non Small Cell Lung Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03970746 | PDC*lung01 | Phase 1 | Non Small Cell Lung Cancer | Oncology | Jul 2024 |
Immunocore Neowise Biotechnology Immatics US OSE Immunotherapeutics Zelluna Immunotherapy CDR-Life USWM CT
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.